SpringerLink
Log in

Matrix metalloproteinases and their pathological upregulation in multiple sclerosis: an overview

  • Review Article
  • Published:
Acta Neurologica Belgica Aims and scope Submit manuscript

Abstract

Matrix metalloproteinases (MMPs) are a family of extracellular proteases associated with extracellular matrix remodeling. They are involved in many physiological and reparative processes. MMPs can break down all extracellular constituents; therefore, their expression is very tightly regulated and their abnormal activity or over production has been linked to many diseases including multiple sclerosis (MS) which is a leading cause of non-traumatic disability in young adults in North America. Recently many studies, both in animals and humans, have been conducted to better elucidate the underlying causes, mechanisms and pathophysiology of MS. In this review, we discuss the potential role of pathological upregulation of MMPs in MS and future challenges which if properly addressed might help in development of potential cure for this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Yong VW et al (2001) Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2(7):502–511

    Article  PubMed  CAS  Google Scholar 

  2. Yong VW (1999) The potential use of MMP inhibitors to treat CNS diseases. Expert Opin Investig Drugs 8(3):255–268

    Article  PubMed  CAS  Google Scholar 

  3. Mott JD, Werb Z (2004) Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 16(5):558–564

    Article  PubMed  CAS  Google Scholar 

  4. Yong VW (2005) Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci 6(12):931–944

    Article  PubMed  CAS  Google Scholar 

  5. Rosenberg GA (2009) Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 8(2):205–216

    Article  PubMed  CAS  Google Scholar 

  6. Brinckerhoff CE, Matrisian LM (2002) Timeline–matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 3(3):207–214

    Article  PubMed  CAS  Google Scholar 

  7. Verma RP, Hansch C (2007) Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. Bioorg Med Chem 15(6):2223–2268

    Article  PubMed  CAS  Google Scholar 

  8. Belvisi M, Bottomley K (2003) The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs? Inflamm Res 52(3):95–100

    Article  PubMed  CAS  Google Scholar 

  9. Georgiadis D, Yiotakis A (2008) Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge. Bioorg Med Chem 16(19):8781–8794

    Article  PubMed  CAS  Google Scholar 

  10. Sternlicht MD, Werb Z (2001) How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17:463–516

    Article  PubMed  CAS  Google Scholar 

  11. Vincenti MP, Brinckerhoff CE (2007) Signal transduction and cell-type specific regulation of matrix metalloproteinase gene expression: can MMPs be good for you? J Cell Physiol 213(2):355–364

    Article  PubMed  CAS  Google Scholar 

  12. Cunningham LA, Wetzel M, Rosenberg GA (2005) Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 50(4):329–339

    Article  PubMed  Google Scholar 

  13. Makowski GS, Ramsey ML (1998) Binding of matrix metalloproteinase 9 to fibrin is mediated by amorphous calcium-phosphate. Inflammation 22(6):599–617

    Article  PubMed  CAS  Google Scholar 

  14. Okada Y et al (1990) Matrix metalloproteinase-2 from human rheumatoid synovial fibroblasts: purification and activation of the precursor and enzymatic-properties. Eur J Biochem 194(3):721–730

    Article  PubMed  CAS  Google Scholar 

  15. Bernal F et al (2009) Regulation of matrix metalloproteinases and their inhibitors by interferon-beta: a longitudinal study in multiple sclerosis patients. Mult Scler 15(6):721–727

    Article  PubMed  CAS  Google Scholar 

  16. Kieseier BC et al (1998) Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 121(Pt 1):159–166

    Article  PubMed  Google Scholar 

  17. Agrawal SM, Lau L, Yong VW (2008) MMPs in the central nervous system: where the good guys go bad. Semin Cell Develop Biol 19:42–51

    Article  CAS  Google Scholar 

  18. Newman TA et al (2001) T-cell- and macrophage-mediated axon damage in the absence of a CNS-specific immune response: involvement of metalloproteinases. Brain 124(Pt 11):2203–2214

    Article  PubMed  CAS  Google Scholar 

  19. Agrawal SM, Yong VW (2007) Immunopathogenesis of multiple sclerosis. Int Rev Neurobiol 79:99–126

    PubMed  CAS  Google Scholar 

  20. Brundula V et al (2002) Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 125(Pt 6):1297–1308

    Article  PubMed  Google Scholar 

  21. Alexander JS et al (2010) Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b. Mult Scler 16(7):801–809

    Article  PubMed  CAS  Google Scholar 

  22. Chandler S et al (1997) Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J Neuroimmunol 72(2):155–161

    Article  PubMed  CAS  Google Scholar 

  23. Benešová Y et al (2009) Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis. Multiple Scler 15(3):316–322

    Article  Google Scholar 

  24. Leppert D et al (1998) Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 121(Pt 12):2327–2334

    Article  PubMed  Google Scholar 

  25. Chandler S et al (1997) Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J Neuroimmunol 72(2):155–161

    Article  PubMed  CAS  Google Scholar 

  26. Gasche Y et al (2006) Matrix metalloproteinases and diseases of the central nervous system with a special emphasis on ischemic brain. Front Biosci 11:1289–1301

    Article  PubMed  CAS  Google Scholar 

  27. Lichtinghagen R et al (1999) Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis. J Neuroimmunol 99(1):19–26

    Article  PubMed  CAS  Google Scholar 

  28. Anthony DC et al (1997) Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol 23(5):406–415

    Article  PubMed  CAS  Google Scholar 

  29. Toft-Hansen H et al (2004) Key metalloproteinases are expressed by specific cell types in experimental autoimmune encephalomyelitis. J Immunol 173(8):5209–5218

    PubMed  CAS  Google Scholar 

  30. Teesalu T, Hinkkanen AE, Vaheri A (2001) Coordinated induction of extracellular proteolysis systems during experimental autoimmune encephalomyelitis in mice. Am J Pathol 159(6):2227–2237

    Article  PubMed  CAS  Google Scholar 

  31. Graesser D et al (1998) The interrelationship of alpha4 integrin and matrix metalloproteinase-2 in the pathogenesis of experimental autoimmune encephalomyelitis. Lab Invest 78(11):1445–1458

    PubMed  CAS  Google Scholar 

  32. Nygardas PT, Hinkkanen AE (2002) Up-regulation of MMP-8 and MMP-9 activity in the BALB/c mouse spinal cord correlates with the severity of experimental autoimmune encephalomyelitis. Clin Exp Immunol 128(2):245–254

    Article  PubMed  CAS  Google Scholar 

  33. Clements JM et al (1997) Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. J Neuroimmunol 74(1–2):85–94

    Article  PubMed  CAS  Google Scholar 

  34. Dasilva AG, Yong VW (2008) Expression and regulation of matrix metalloproteinase-12 in experimental autoimmune encephalomyelitis and by bone marrow derived macrophages in vitro. J Neuroimmunol 199(1–2):24–34

    Article  PubMed  CAS  Google Scholar 

  35. Goncalves DaSilva A, Liaw L, Yong VW (2010) Cleavage of osteopontin by matrix metalloproteinase-12 modulates experimental autoimmune encephalomyelitis disease in C57BL/6 mice. Am J Pathol 177(3):1448–1458

    Article  PubMed  Google Scholar 

  36. Rosenberg GA (2002) Matrix metalloproteinases and neuroinflammation in multiple sclerosis. Neuroscientist 8(6):586–595

    Article  PubMed  CAS  Google Scholar 

  37. Rosenberg GA et al (1992) TIMP-2 reduces proteolytic opening of blood–brain barrier by type IV collagenase. Brain Res 576(2):203–207

    Article  PubMed  CAS  Google Scholar 

  38. Rosenberg GA et al (1994) Injury-induced 92-kilodalton gelatinase and urokinase expression in rat brain. Lab Invest 71(3):417–422

    PubMed  CAS  Google Scholar 

  39. Rosenberg GA et al (1995) Tumor necrosis factor-alpha-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window. Brain Res 703(1–2):151–155

    Article  PubMed  CAS  Google Scholar 

  40. Shiryaev SA et al (2009) Matrix metalloproteinase proteolysis of the myelin basic protein isoforms is a source of immunogenic peptides in autoimmune multiple sclerosis. PLoS One 4(3):e4952

    Article  PubMed  Google Scholar 

  41. Latronico T et al (2013) Inhibition of myelin-cleaving poteolytic activities by interferon-beta in rat astrocyte cultures. Comparative analysis between gelatinases and calpain-II. PLoS One 8(2):e49656

    Article  PubMed  CAS  Google Scholar 

  42. Niimi N, Kohyama K, Matsumoto Y (2013) Minocycline suppresses experimental autoimmune encephalomyelitis by increasing tissue inhibitors of metalloproteinases. Neuropathology

  43. Marracci GH et al (2002) Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J Neuroimmunol 131(1–2):104–114

    Article  PubMed  CAS  Google Scholar 

  44. Dubois B et al (1999) Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J Clin Invest 104(11):1507–1515

    Article  PubMed  CAS  Google Scholar 

  45. Yong VW et al (2007) Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immuno modulators. J Neurol Sci 259(1–2):79–84

    Article  PubMed  CAS  Google Scholar 

  46. Folgueras AR et al (2008) Collagenase-2 deficiency or inhibition impairs experimental autoimmune encephalomyelitis in mice. J Biol Chem 283(14):9465–9474

    Article  PubMed  CAS  Google Scholar 

  47. Shipley JM et al (1996) Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci USA 93(9):3942–3946

    Article  PubMed  CAS  Google Scholar 

  48. Gijbels K et al (1992) Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 41(1):29–34

    Article  PubMed  CAS  Google Scholar 

  49. Cuzner ML, Opdenakker G (1999) Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J Neuroimmunol 94(1–2):1–14

    Article  PubMed  CAS  Google Scholar 

  50. Lee MA et al (1999) Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain 122(Pt 2):191–197

    Article  PubMed  Google Scholar 

  51. Fernandes KS et al (2009) Matrix metalloproteinase-9 genotypes and haplotypes are associated with multiple sclerosis and with the degree of disability of the disease. J Neuroimmunol 214(1–2):128–131

    Article  PubMed  CAS  Google Scholar 

  52. Benesova Y et al (2012) An Association between matrix metalloproteinase-2 and TIMP-2 + 853G/A gene polymorphisms and multiple sclerosis. Česká a slovenská neurologie a neurochirurgie 75(3):314–319

    CAS  Google Scholar 

  53. Benesova Y et al (2008) Matrix metalloproteinase-9 and matrix metalloproteinase-2 gene polymorphisms in multiple sclerosis. J Neuroimmunol 205(1–2):105–109

    Article  PubMed  CAS  Google Scholar 

  54. Liuzzi GM et al (2002) Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. Mult Scler 8(3):222–228

    Article  PubMed  CAS  Google Scholar 

  55. Lindberg RL et al (2001) The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain 124(Pt 9):1743–1753

    Article  PubMed  CAS  Google Scholar 

  56. Cossins JA et al (1997) Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol 94(6):590–598

    Article  PubMed  CAS  Google Scholar 

  57. Maeda A, Sobel RA (1996) Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 55(3):300–309

    Article  PubMed  CAS  Google Scholar 

  58. Cuzner ML et al (1996) The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol 55(12):1194–1204

    Article  PubMed  CAS  Google Scholar 

  59. Bar-Or A et al (2003) Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain 126(12):2738–2749

    Article  PubMed  Google Scholar 

  60. Apodaca G et al (1990) Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cells. Cancer Res 50(8):2322–2329

    PubMed  CAS  Google Scholar 

  61. Uhm JH et al (1999) Migratory behavior of lymphocytes isolated from multiple sclerosis patients: effects of interferon beta-1b therapy. Ann Neurol 46(3):319–324

    Article  PubMed  CAS  Google Scholar 

  62. Deb S, Gottschall PE (1996) Increased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with beta-amyloid peptides. J Neurochem 66(4):1641–1647

    Article  PubMed  CAS  Google Scholar 

  63. Yong VW et al (1998) Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 21(2):75–80

    Article  PubMed  CAS  Google Scholar 

  64. Gray E et al (2008) Elevated matrix metalloproteinase-9 and degradation of perineuronal nets in cerebrocortical multiple sclerosis plaques. J Neuropathol Exp Neurol 67(9):888–899

    Article  PubMed  Google Scholar 

  65. Ozenci V et al (2000) Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta. J Neuroimmunol 108(1–2):236–243

    Article  PubMed  CAS  Google Scholar 

  66. Stuve O et al (1996) Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 40(6):853–863

    Article  PubMed  CAS  Google Scholar 

  67. Leppert D et al (1996) Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 40(6):846–852

    Article  PubMed  CAS  Google Scholar 

  68. Trojano M et al (1999) Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 53(7):1402–1408

    Article  PubMed  CAS  Google Scholar 

  69. Moss ML et al (2001) TACE and other ADAM proteases as targets for drug discovery. Drug Discov Today 6(8):417–426

    Article  PubMed  CAS  Google Scholar 

  70. Larsen PH et al (2003) Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan. J Neurosci 23(35):11127–11135

    PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

Author information

Authors and Affiliations

  1. Division of Biomedical Sciences, Faculty of Dentistry, McGill University, 3640 University Street, Montreal, QC, H3A 0C7, Canada

    Mohammad A. Javaid, Mohamed-Nur Abdallah & Zeeshan Sheikh

  2. Division of Restorative Dentistry, Faculty of Dentistry, McGill University, 3640 University Street, Montreal, QC, H3A 0C7, Canada

    Mohamed-Nur Abdallah

  3. Department of Dentistry, Jewish General Hospital/McGill University, 3755 Cote Ste Catherine, Suite H416.2, Montreal, QC, H3T 1E2, Canada

    Ahad S. Ahmed

  4. Department of Material Sciences and Preclinical Dentistry, Altamash Institute of Dental Medicine, Karachi, Pakistan

    Zeeshan Sheikh

  5. Department of Oral Anatomy, Altamash Institute of Dental Medicine, Karachi, Pakistan

    Zeeshan Sheikh

Authors
  1. Mohammad A. Javaid
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohamed-Nur Abdallah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ahad S. Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zeeshan Sheikh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohamed-Nur Abdallah.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Javaid, M.A., Abdallah, MN., Ahmed, A.S. et al. Matrix metalloproteinases and their pathological upregulation in multiple sclerosis: an overview. Acta Neurol Belg 113, 381–390 (2013). https://doi.org/10.1007/s13760-013-0239-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13760-013-0239-x

Keywords

Search

Navigation